Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.39 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280714 | 0.80 | SLC6A4 (0.45) | MAP2K1HSD11B1SLC6A4MTNR1AOPRL1 | |
| SCHEMBL14529648 | 0.80 | SLC6A4 (0.45) | MAP2K1HSD11B1SLC6A4MTNR1AOPRL1 | |
| SCHEMBL818489 | 0.79 | MTNR1A (0.48) | MAP2K1SLC6A4MTNR1A | |
| SCHEMBL820684 | 0.79 | MTNR1A (0.48) | MAP2K1SLC6A4MTNR1A | |
| SCHEMBL5766451 | 0.70 | POLB (0.40) | — | |
| SCHEMBL5766449 | 0.70 | POLB (0.40) | — | |
| SCHEMBL5766457 | 0.70 | POLB (0.40) | — | |
| SCHEMBL2262735 | 0.69 | OPRL1 (0.59) | HSD11B1SLC6A4OPRL1OPRM1OPRK1 | |
| SCHEMBL29869395 | 0.69 | OPRL1 (0.59) | HSD11B1SLC6A4OPRL1OPRM1OPRK1 | |
| SCHEMBL2511843 | 0.69 | SLC22A6 (0.58) | MAP2K1MTNR1ACAMKK2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | MAP2K1 3375/4885HSD11B1 4278/4885SLC6A4 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.